Stock Evaluator: Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics, Inc. PLX

$2.60 0.01 0.39%
September 3, 2026 9:30:36 AM EST November 10, 2021 Volume: 24,044
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD AMEX | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Commentary & Analysis


Financial Summary

Share Statistics PLX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $208.7 $288.9 27%
Shares Out (Mil) 82.6 54.0 58%
Institutional Ownership 83.2% 93.1% 51%
Float (Mil) 77.4 41.4 56%
Beta 0.01 0.94 6%
Avg Daily Volume (000s) 655 480 64%
Price Change
(52-week)
57.9% 59.9% 83%
Growth PLX Industry
Median
Percentile
(All Stocks)
Sales (5yr) (3.5%) 14.1% 10%
Net Income (5yr) (0.3%) (10.1%) 39%
EPS (5yr) 17.8% 15.9% 64
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (38.0%) (15.6%) 13%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials PLX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $81 $37 24%
Net Income (TTM) (Mil) $19 ($43) 49%
EPS (TTM) $0.238 ($1.500) 48%
Operating Cash Flow (TTM) (Mil) $10 ($31) 38%
Net Cash Flow (TTM) (Mil) $10 $2 56%
Long-Term Debt (Q1) (Mil) $8 $4 27%
Enterprise Value (Q1) (Mil) $180 $190 25%
Valuation PLX Industry
Median
Percentile
(All Stocks)
P/B 2.91 2.84 64%
P/E 11.0 20.0 20%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.6 1.1 30%
Ratios PLX Industry
Median
Percentile
(All Stocks)
Gross Margin 45.8% 66.9% 57%
Net Margin 23.5% (74.2%) 82%
ROA 20.1% (47.7%) 96%
ROE 31.2% (55.0%) 88%
Liabilities to Assets 35.3% 29.6% 26%
F-Score 6 3 67%

Passing Stock Screens

As of 9/2/2026, from a list of 60 stock screening strategies, PLX meetings the criteria of 1 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors